Skip to content

Geron GERN Business Segments — Net loss

Similar metrics at other companies

Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — Net loss
-$6.97M+72.3%
Bicara Therapeutics logo
BCAXReportable Segment — Net loss
-$56.21M-52.6%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Net loss
-$127.85M-32.1%
Biohaven logo
BHVNReportable Segment — Net loss
-$130.53M+41.1%
Lexicon Pharmaceuticals logo
LXRXReportable Segment — Net loss
-$1.04M+95.9%
Ouster logo
OUSTReportable Segment — Net loss
-$17.47M+20.7%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's business segments — net loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's business segments — net loss?
Geron (GERN) reported business segments — net loss of -$3.6M in Q1 2026.
How has Geron's business segments — net loss changed year-over-year?
Geron's business segments — net loss increased by 81.8% year-over-year, from -$19.8M to -$3.6M.
What does business segments — net loss mean?
Represents the final bottom-line result for the segment after accounting for all revenues, operating expenses, restructuring charges, and non-operating items. A persistent net loss is typical for clinical-stage biopharmaceutical segments heavily invested in long-term research and development.